Carta al Editor
Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: coment
Read
2202
Timeswas read the article
344
Total PDF
1858
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 April | 70 | 14 | 84 |
| 2024 March | 84 | 35 | 119 |
| 2024 February | 70 | 31 | 101 |
| 2024 January | 78 | 34 | 112 |
| 2023 December | 50 | 24 | 74 |
| 2023 November | 65 | 39 | 104 |
| 2023 October | 85 | 42 | 127 |
| 2023 September | 92 | 53 | 145 |
| 2023 August | 75 | 23 | 98 |
| 2023 July | 9 | 0 | 9 |
| 2023 June | 13 | 6 | 19 |
| 2023 May | 10 | 3 | 13 |
| 2023 April | 6 | 0 | 6 |
| 2023 March | 37 | 8 | 45 |
| 2023 February | 12 | 8 | 20 |
| 2023 January | 22 | 0 | 22 |
| 2022 December | 41 | 2 | 43 |
| 2022 November | 41 | 0 | 41 |
| 2022 October | 40 | 4 | 44 |
| 2022 September | 49 | 2 | 51 |
| 2022 August | 41 | 0 | 41 |
| 2022 July | 58 | 6 | 64 |
| 2022 June | 78 | 2 | 80 |
| 2022 May | 169 | 2 | 171 |
| 2022 April | 334 | 2 | 336 |
| 2022 March | 229 | 4 | 233 |
Show all
